New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .
The New England Journal of Medicine: Search Results in Hematology/Oncology
NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .
The New England Journal of Medicine: Search Results in Hematology/Oncology
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of chemotherapy.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Ponsegromab for the Treatment of Cancer Cachexia
The monoclonal antibody ponsegromab increased weight, improved appetite, and led to increased physical activity in patients with cancer cachexia who had lost weight during the previous 6 months.
The New England Journal of Medicine: Search Results in Hematology/Oncology
NEJM at ESMO — Ponsegromab in Cancer Cachexia
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .
The New England Journal of Medicine: Search Results in Hematology/Oncology
No One in Charge
A chance encounter with a retired military officer who recently lost his wife to cancer raises questions for a retired pediatrician about medical hierarchy, team leadership, and appropriate care.
The New England Journal of Medicine: Search Results in Hematology/Oncology